Ipilimumab: controversies in its development, utility and autoimmune adverse events

[1]  J. Weber,et al.  Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multipeptide vaccine for resected stages IIIC and IV melanoma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  S. O’Day,et al.  Phase I/II study of ipilimumab for patients with metastatic melanoma. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  T. Nomura,et al.  CTLA-4 Control over Foxp3+ Regulatory T Cell Function , 2008, Science.

[4]  P. Sharma,et al.  CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients , 2008, Proceedings of the National Academy of Sciences.

[5]  L. Zitvogel,et al.  CTLA-4 Blockade Confers Lymphocyte Resistance to Regulatory T-Cells in Advanced Melanoma: Surrogate Marker of Efficacy of Tremelimumab? , 2008, Clinical Cancer Research.

[6]  S. Chanock,et al.  Influence of Cytotoxic T Lymphocyte-associated Antigen 4 (CTLA4) Common Polymorphisms on Outcome in Treatment of Melanoma Patients With CTLA-4 Blockade , 2008, Journal of immunotherapy.

[7]  H. Pehamberger,et al.  Novel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibody , 2008 .

[8]  H. Pehamberger,et al.  Efficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapies , 2008 .

[9]  A. Pavlick,et al.  Disease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX- 010) with or without dacarbazine , 2008 .

[10]  G. Linette,et al.  Dose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging study , 2008 .

[11]  O. Hamid,et al.  Safety and efficacy of ipilimumab with or without prophylactic budesonide in treatment-naive and previously treated patients with advanced melanoma , 2008 .

[12]  S. O’Day,et al.  Long-term survival of patients with advanced melanoma who received ipilimumab administered at 10 mg/kg every 3 weeks for 4 doses (induction dosing) , 2008 .

[13]  J. Wolchok,et al.  Antitumor response and new lesions in advanced melanoma patients on ipilimumab treatment , 2008 .

[14]  D. Neuberg,et al.  Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients , 2008, Proceedings of the National Academy of Sciences.

[15]  J. Wolchok,et al.  The heterogeneity of the kinetics of response to ipilimumab in metastatic melanoma: patient cases. , 2008, Cancer immunity.

[16]  S. Steinberg,et al.  Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade , 2007, Clinical Cancer Research.

[17]  J. Weber.  Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. , 2007, The oncologist.

[18]  F. Hodi,et al.  Kinetics of response to ipilimumab (MDX-010) in patients with stage III/IV melanoma , 2007 .

[19]  S. O’Day,et al.  The efficacy and safety of ipilimumab (MDX-010) in patients with unresectable stage III or stage IV malignant melanoma , 2007 .

[20]  S. Rosenberg,et al.  Intrapatient Dose Escalation of Anti–CTLA-4 Antibody in Patients With Metastatic Melanoma , 2006, Journal of immunotherapy.

[21]  S. Targan,et al.  Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected stages IIIC and IV melanoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  A. Feldman,et al.  Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Rosenberg,et al.  Analysis of the Cellular Mechanism of Antitumor Responses and Autoimmunity in Patients Treated with CTLA-4 Blockade , 2005, The Journal of Immunology.

[24]  S. Rosenberg,et al.  Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  A. Pavlick,et al.  DURABLE RESPONSES AND LONG-TERM PROGRESSION- FREE SURVIVAL OBSERVED IN A PHASE II STUDY OF MDX- 010 ALONE OR IN COMBINATION WITH DACARBAZINE (DTIC) IN METASTATIC MELANOMA. , 2005 .

[26]  S. Groshen,et al.  Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  S. Rosenberg,et al.  Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer. , 2005, Journal of immunotherapy.

[28]  J. Egen,et al.  B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. , 2004, Immunity.

[29]  J. A. Bishop.  Molecular pathology of melanoma , 1997, Cancer and Metastasis Reviews.

[30]  Thomas A. Davis,et al.  Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[31]  Thomas Davis,et al.  Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[32]  J. Egen,et al.  CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. , 2001, Annual review of immunology.

[33]  J. Allison,et al.  CTLA-4--the costimulatory molecule that doesn't: regulation of T-cell responses by inhibition. , 1999, Cold Spring Harbor symposia on quantitative biology.

[34]  T. Sullivan,et al.  Lymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cells. , 1997, Immunity.

[35]  J. Allison,et al.  Enhancement of Antitumor Immunity by CTLA-4 Blockade , 1996, Science.

[36]  J. Allison,et al.  CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation , 1995, The Journal of experimental medicine.